Back to results
US 2024/0165158 A1Published application
Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases
AssigneeJura Bio, Inc.
InventorsJulie Norville, Elizabeth Wood
Life of this patent
Estimating the term…
Abstract
Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.
Claims27
A major histocompatibility complex (MHC)-based chimeric receptor, comprising:
- (i) an extracellular domain of a MHC molecule conjugated to an antigenic peptide from an antigen involved in an autoimmune disease;
- and
- (ii) a cytoplasmic signaling domain, at least one co-stimulatory domain, or a combination thereof;
- wherein the MHC molecule is a class I MHC.
1 more element
(canceled)
13-20. (canceled)
24-41. (canceled)
(canceled)
45-48. (canceled)
50-53. (canceled)
55-57. (canceled)
59-76. (canceled)
Dependencies are inferred from the claim text.